Prostate Cancer Reports



Volume 3 Number 5
  May 2015
Home > Prostate Cancer Reports > Volume 3, Year 2015 > Number 5, May

CONTENTS



Detection, diagnosis and evaluation
Etiology and pathogenesis
Prognosis and outcome
Treatment


DETECTION, DIAGNOSIS AND EVALUATION



Cimitan M, Evangelista L, Hodolič M, Mariani G, Baseric T, Bodanza V, Saladini G, Volterrani D, Cervino AR, Gregianin M, Puccini G, Guidoccio F, Fettich J, Borsatti E.
Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
J Nucl Med. 2015 Feb;56(2):209-15. doi: 10.2967/jnumed.114.141887. Epub 2014 Dec 31.
Abstract | Related citations


Simone G, Di Pierro GB, Papalia R, Sciuto R, Rea S, Ferriero M, Guaglianone S, Maini CL, Gallucci M.
Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with 18F-fluorocholine positron emission tomography/computed tomography.
World J Urol. 2015 Jan 11. [Epub ahead of print]
Abstract | Related citations


Restaging

Sweeney L, Cox A, Kynaston H, Hughes O, Rees J, Staffurth J.
Findings of Restaging Imaging Prior to Salvage Radiotherapy for Biochemical Relapse Following Radical Prostatectomy

Clin Oncol, March 2015, Vol 27, Issue 3, Pages e5–e6.
Abstract | Related citations

ETIOLOGY AND PATHOGENESIS



Ganguly SS, Li X, Miranti CK.
The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.
Front Oncol. 2014 Dec 15;4:364. doi: 10.3389/fonc.2014.00364. eCollection 2014.
Abstract | Full text | Related citations

PROGNOSIS AND OUTCOME



Azvolinsky A.
Higher Cholesterol Levels Linked to Prostate Cancer.
Oncology (Williston Park). 2014 Oct 14.
Abstract | Full text


Azvolinsky A.
Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
Oncology (Williston Park). 2013 May 13.
Abstract | Full text


Gallina A, Bianchi M, Gandaglia G, Cucchiara V, Suardi N, Montorsi F, Briganti A.
A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy.
Eur Urol. 2015 Feb 17. pii: S0302-2838(15)00077-9. doi: 10.1016/j.eururo.2015.02.002. [Epub ahead of print]
Abstract | Related citations


Hashimoto K, Mizuno T, Kitamura H, Shindo T, Takahashi S, Masumori N.
The primary local stage at diagnosis predicts regional symptoms caused by local progression in patients with castration-resistant prostate cancer.
Urology. 2015 Feb;85(2):430-5. doi: 10.1016/j.urology.2014.09.044.
Abstract | Related citations


Hsu CC, Paciorek AT, Cooperberg MR, Roach M 3rd, Hsu IC, Carroll PR.
Post-operative Radiation Therapy for Patients at High-risk of Recurrence after Radical Prostatectomy: Does Timing Matter?
BJU Int. 2015 Jan 20. doi: 10.1111/bju.13043. [Epub ahead of print]
Abstract | Related citations


Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ.
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
Cancer. 2014 Dec 9. doi: 10.1002/cncr.29147. [Epub ahead of print]
Abstract | Related citations


Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ.
Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Int J Urol. 2015 Feb 24. doi: 10.1111/iju.12704. [Epub ahead of print]
Abstract | Related citations


Özkanli SŞ, Zemher IE, Yildirim A, Gür HD, Balbay MD, Şenol S, Özkanli AO, Alkan E, Zenginkinet T, Aydin A, Çaşkurlu T.
Gleason score at the margin can predict biochemical recurrence after radical prostatectomy, in addition to preoperative PSA and surgical margin status.
Turk J Med Sci. 2014;44(3):397-403. Epub 2014 Mar 31.
Abstract | Full text | Related citations


Preston MA, Breau RH, Lantz AG, Morash C, Gerridzen RG, Doucette S, Mallick R, Eastham JA, Cagiannos I.
The association between nerve sparing and a positive surgical margin during radical prostatectomy.
Urol Oncol. 2015 Jan;33(1):18.e1-6. doi: 10.1016/j.urolonc.2014.09.006. Epub 2014 Oct 11.
Abstract | Full text | Related citations


Rizk J, Ouzzane A, Flamand V, Fantoni JC, Puech P, Leroy X, Villers A.
[Long term biochemical recurrence free survival after radical prostatectomy for cancer: Comparative analysis according to surgical approach and clinicopathological stage].
Prog Urol. 2015 Mar;25(3):157-68. doi: 10.1016/j.purol.2014.12.004. Epub 2015 Jan 19. French.
Abstract | Related citations


Simon RM, Salama JK, Freedland SJ.
Radical Prostatectomy versus Radiation Therapy: Can Pretreatment Nomograms Be Used to Select the Appropriate Prostate Cancer Treatment?
Eur Urol. 2014 Oct 28. pii: S0302-2838(14)01017-3. doi: 10.1016/j.eururo.2014.10.009. [Epub ahead of print]
Abstract | Full text | Related citations


Smith GD, Pickles T, Crook J, Martin AG, Vigneault E, Cury FL, Morris J, Catton C, Lukka H, Warner A, Yang Y, Rodrigues G.
Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):505-16. doi: 10.1016/j.ijrobp.2014.11.018. Epub 2015 Jan 13.
Abstract | Related citations


Watkins JM, Watkins PL, Dufan TA, Koleilat N.
What Is the Optimal Management of Gleason Score 7 Prostate Cancer at Biopsy? A Comparison of Disease Control for Prostatectomy Versus Radiotherapy.
Clin Genitourin Cancer. 2014 Oct 2. pii: S1558-7673(14)00209-2. doi: 10.1016/j.clgc.2014.09.002. [Epub ahead of print]
Abstract | Related citations

TREATMENT



Anna Azvolinsky, PhD
Anna Azvolinsky, PhD
Azvolinsky A.
Delaying ADT Safe for Prostate Cancer Patients.
Oncology (Williston Park). 2014 May 19.
Abstract | Full text


D'Amico AV.
Personalizing the duration of androgen-deprivation therapy use in the management of intermediate-risk prostate cancer.
J Clin Oncol. 2015 Feb 1;33(4):301-3. doi: 10.1200/JCO.2014.59.0968. Epub 2014 Dec 22.
Abstract | Full text | Related citations


Garcia-Albeniz X, Chan JM, Paciorek AT, Logan RW, Kenfield SA, Cooperberg MR, Caroll P, Hernan M.
Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse.
2014 ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL). J Clin Oncol 32:5s, 2014 (suppl; abstr 5003).
Abstract | Full text


Hou CP, Lee WC, Lin YH, Chen SM, Chen CL, Chang PL, Juang HH, Tsui KH.
Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer.
Onco Targets Ther. 2014 Dec 17;8:15-9. doi: 10.2147/OTT.S73925. eCollection 2015.
Abstract | Full text | Related citations


Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci MA, Force T, Kelly WK.
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.
Am J Cancer Ther Pharmacol. 2014 Sep 7;2(1):21-32.
Abstract | Full text | Related citations


Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM.
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
J Clin Oncol. 2015 Feb 1;33(4):332-9. doi: 10.1200/JCO.2014.58.0662. Epub 2014 Dec 22.
Abstract | Related citations